Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on Femasys (FEMY – Research Report) and keeping the price target at $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emily Bodnar has given her Buy rating due to a combination of factors, including the strategic partnerships Femasys has established with prominent fertility clinics. The recent collaboration with Carolinas Fertility Institute, along with existing partnerships with Boston IVF, CNY Fertility, and HRC Fertility, expands FemaSeed’s reach to over 60 clinics across the United States. This represents nearly 20% of the fertility clinics in the country, indicating a strong market penetration since its approval in September 2023. The anticipated growth in revenue from these partnerships is expected to manifest primarily in the second half of 2025, as clinics begin to utilize the FemaSeed treatment.
Furthermore, the Buy rating is supported by a discounted cash flow analysis, which projects a $12 price target. The analysis considers a 15% discount rate and extends estimates to 2038, with a 100% probability of success for FemaSeed. While there are risks such as potential safety signals, efficacy issues, and regulatory concerns, the current valuation reflects a positive outlook for Femasys’ financial performance, particularly with the expected revenue growth from its women’s health offerings in 2025.